Skip to Main Content

Paper Details

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with â¿¥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Eur J Cancer
160
2019
Author NameAffiliation
Antonio JimenoUniversity of Colorado School of Medicine
Lillian L SiuPrincess Margaret Cancer Centre, University of Toronto
  • 1 - 2

Datasets

Release 1.2